MINI REVIEW

Non-coding RNAs open a new chapter in liver cancer treatment

Angélique Gougelet*, Christèle Desbois-Mouthon

Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Team ''Oncogenic functions of beta-catenin signaling in the liver'', 75006 Paris, France

Available online 7 August 2019

Summary   Despite the intensive efforts to identify the molecular events responsible for the emergence of liver cancer, hepatocellular carcinoma (HCC) remains a major health problem in the world. Thus, the identification of new therapeutic opportunities is a short-term necessity. These last few decades, non-coding RNAs appeared as interesting therapeutic strategies with their pleiotropic inhibitory action in the cell itself but also in recipient cells via their secretion into extracellular vesicles. This short review recapitulates recent advancements concerning non-coding RNAs and their deregulations in liver cancer.
© 2019 Elsevier Masson SAS. All rights reserved.

Introduction

For decades, proteins were believed to carry hereditary information, in particular during bacterial transformation described by the microbiologist Frederick Griffith in 1928.

Nevertheless, fifteen years later, this precept was questioned by the experiment of Oswald Avery, Colin MacLeod, and Maclyn McCarty in 1944, which demonstrated that DNA was the hereditary genetic material controlling the pathogenicity of the bacteria [1]. After years of consolidating experiments, the scientific community assumed that DNA makes us who we are. Therefore, over several decades, proteins that result from DNA genetic information were credited to be the master regulators of cell behavior. It had to wait for the 2000s and the opportunity of whole exome sequencing to crush the concept of DNA world and open the new era of a RNA world. Indeed, the human genome only contains a tiny fraction of protein-coding genes, supporting that RNA play a more substantial role than originally believed [2]. The rest of the genome is nonetheless actively transcribed into RNAs without coding potential, and called non-coding RNAs (ncRNAs). NcRNAs are partitioned into repetitive DNA, which constitute the largest fraction (40-50%), including:

- telomeres;
- transposable elements (long (LINE) and short interspersed nuclear elements (SINE));
- introns (approximately 25%);
- miscellaneous sequences [3].

Non-protein-coding DNA sequences, once considered as junk DNAs, proportionally increase with evolution complexity from prokaryotes to mammals, reaching more than 98% of the human genome ([4] for a review). This discovery has shaken the conscience and largely modified our understanding of complex diseases like cancer. Scientists now face major issues to unveil the precise biological functions of these non-coding RNAs and the impact of their deregulations in pathological processes. And, even if crucial roles in gene regulations have been assigned to a great majority of these sequences, non-coding RNAs globally remain a mysterious world to explore.

Non-coding RNA biogenesis

NcRNAs are arbitrarily divided into two categories, small (< 200 nucleotides (nt)) and long non-coding RNAs (lncRNAs) (>200 nucleotides) [5]. Small ncRNAs notably include:

- Piwi-interacting RNAs (piRNAs), mainly identified in germ cells to silence genetic elements such as transposons [6];
- small nucleolar RNAs (snoRNAs), that guide chemical modifications of other RNAs [7];
- small nuclear RNAs (snRNAs), found within the spliceosome [8];
- the most widely characterized ncRNAs, the microRNAs (miRNAs), involved in post-transcriptional gene silencing [9].

Long non-coding RNAs are generally 1,000—10,000 residues in length and refer to natural antisense transcripts and other regulatory long non-coding RNAs [10]. Based on their proximity to protein-coding genes, miRNAs and lncRNAs have been classified into exonic, intronic and intergenic ncRNAs and quite commonly produced in a polycistronic manner. Although biogenesis and biological functions differ for all ncRNAs, and more notably for lncRNAs, small ncRNA biogenesis shares several similarities with RNA interference pathway [11] (Fig. 1). RNA-processing proteins usually cleave primary transcripts of small ncRNAs into small RNA fragments. Then, processed ncRNAs are loaded into the multi-protein machinery called RISC (*RNA-induced silencing complex*), which helps in Argonaute recruitment. Argonaute proteins are evolutionarily conserved and phylogenetically subdivided into the Ago subclass, for miRNA and siRNA processing, and the Piwi subfamily that binds to piRNAs [12]. Both Argonaute protein subfamilies have the common capacity to repress gene expression following binding of associated small guiding RNAs on complementary seed sequences in target genes.

In contrast, lncRNA biogenesis shares many features with protein-coding RNAs. LncRNAs are often 5′-capped, spliced and 3′ polyadenylated, but they are shorter in length, do not possess open-reading frames and are expressed in lower abundance. After processing, lncRNA play scaffolding roles to form ribonucleoprotein complexes (RNP) without processing activity. Growing evidence points that lncRNA functions are associated with their subcellular localization [13]. They function as signal, decoy, scaffold, guide or enhancer, to promote chromatin modification, transcription, translation, splicing, mRNA decay, protein transport and assembly [14].

Recently, the landscape of ncRNAs has been remarkably expanded with the emergence of next-generation sequencing and the development of robust bioinformatics tools [15]. In particular, the pattern of human piRNAs switched from about 32,000 identified piRNA sequences in 2014 to reach 8 millions in the second piRBase release published in 2018 [16]. Similarly, Lncipedia catalogs around 50,000 genes of LnRNAs in human [17], while miRBase refers 1,917 human miRNAs, a number in continuous increase [18]. Finally, another widespread and abundant class of non-coding RNAs has been identified in 2012 with the improvement of deep-sequencing, which is called circular RNAs (circRNAs). These RNAs transcriptionally produced from thousand of genes exhibit covalently linked 3′ and 5′ ends and frequently show a higher expression than their linear isoforms [19].

NcRNAs and liver cancer

These recent decades, researchers have paid growing interest for ncRNAs due to their pleiotropic regulating potentials and their ubiquitous distribution in mammalian cells. Now, ncRNAs are defined as versatile cellular switch for good or ill. Accordingly to several deregulations in ncRNA expression observed in various tumors, it is not surprising that the numbers of publications concerning ncRNAs and cancer are constantly increasing: slowly for snoRNAs and piRNAs, reported to be associated with cancer these last years (123 and 186 items in PUBMED respectively), but more intensively for LncRNA (5,182 items) and miRNAs (16,358 items). CircRNAs have already reached 84 items with cancer. Their potential as non-invasive prognostic and predictive biomarkers is substantial since ncRNAs have been detected in a great diversity of body fluids, such as blood, urine and saliva.

microRNAs

Since their discovery at the end of the 1990s, miRNAs are the best-characterized small ncRNAs. The transcription of primary transcripts of miRNAs (pri-miRNAs) is firstly driven by the RNA polymerase II. In about 15% of cases, pri-miRNAs derive from polycistronic miRNA transcripts. Pri-miRNAs are processed by specific complexes of proteins containing Drosha and Dicer, to become mature (pre-miRNAs). Then, they are integrated in RISC complexes to match with complementary sequences mainly located in the 3′UTR (untranslated transcribed region) of mRNAs, resulting in most cases in translation inhibition and accelerated mRNA degradation in subcellular compartments called processing bodies (P-bodies) [20,21]. MiRNAs are from 16 to 35 nucleotides in size. MiRNA expression levels are tissue-specific and finely regulate a precise pattern of genes during growth and development. A modification in cellular

**Figure 1** The great diversity of biogenesis and action of non-coding RNA world. NcRNAs are divided into small ncRNAs (< 200 nt) including piRNAs, snoRNAs and miRNAs, and long non-coding RNAs (> 200 nt) consisting of lncRNAs and circRNAs. Pre-miRNAs processed from pri-miRNAs are integrated in RISC complexes to impair translation and accelerate mRNA degradation. SnoRNAs serve as guides for the 2′-O-methylation chemical and pseudouridylation of other RNAs. piRNAs are produced from long single-stranded piRNA clusters and engaged into a ping-pong cycle to protect the genome from transposon invasion. LncRNAs control transcription, either positively or negatively, mRNA stability and translation and chromatin architecture. circRNAs generated by alternative splicing of pre-mRNAs act as microRNA sponges and transcriptional and translational modulators. This landscape of ncRNAs finely regulate gene program and thus cell function and fate. Disequilibrium in their expression could favor liver disease and promote liver tumorigenesis. NcRNAs could also be secreted from tumor and immune cells into exosomes to modulate cell fate in their neighborhood or at a distance to favor metastasis. CircRNA: circular RNA, LncRNA: long non-coding RNA, miRNA: microRNA, MVB: multivesicular bodies, P-bodies: processing bodies, Pi-P-bodies: processing bodies for piRNAs, piRNA: PiwiRNA, snoRNA: small nucleolar RNA.

miRNA expression is also largely described in a variety of tumors. MiRNA signature can be characteristic of each tumor type in line with its tissue origin and the driven molecular alterations [22]. By their multiplicity of action and their tissue-specific distribution, miRNAs have been pointed as robust therapeutic candidates, and potent biomarkers for cancer diagnosis.

MiRNA expression has been largely found disturbed during hepatocarcinogenesis [23], with specific miRNA deregulations at each step before HCC development, from liver disease to cirrhosis [24]. MiR-122 emerges as the most hopeful miRNA with diagnostic, prognostic and therapeutic potentials. It is the most abundant miRNA in the adult liver, whose expression is largely altered during non-alcoholic steatohepatitis [25] and in HCC, in the liver/tumor but also in the serum [26]. This year, Teufel and coworkers have identified a plasmatic signature of nine miRNAs including miR-122 (miR-122, miR-30a, miR-125b, miR-200a, miR-374b, miR-15b, miR-107, miR-320, and miR-645), which is

significantly associated with patient overall survival during regorafenib treatment [27]. In addition, miR-135a, a miRNA upregulated in HCC [28], has been also described as a promising prognostic factor [29], since its expression is associated with recurrence after tumor resection [30].

In addition to their prognostic benefit, miRNAs could also be useful as therapeutic opportunities in HCC. Importantly, the first miRNA-based therapy to enter into clinical trials was an anti-miR-122 against hepatitis C virus based on the locked nucleic acid technology (LNA)—the virus perverting miR-122 in hepatocytes for its replication [31]. MiRNA-based therapies appear as promising therapeutic strategies as they simultaneously impact on proliferation, metabolic features and immune contexture of liver tumors. MiRNA-based therapies have been successfully tested in liver diseases and cancers (LNA against miR-34a, 2-O-metoxyethyl anti-miR-191) [24,32] — this type of molecules being preferentially delivered to the liver [33]. Mimic-based therapies have also been tested to increase the expression of tumor suppressive

miRNAs. Mimics of miR-34a and Let-7 encapsulated into liposomes have been developed by the miRNAtherapeutics company and tested in HCC. Despite interesting results, their use in patients has been limited because of offside effects of mimics and/or toxicity of liposomes leading to immune dysfunction [34]. A number of challenges are yet to be addressed to improve the efficiency of miRNA-based therapies and reduce the current limitations concerning their stability, administration, specificity, distribution and secondary effects. The recent use of endogenous vesicles called exosomes could be a promising alternative, as developed at the end of this review.

Small nucleolar RNAs

SnoRNAs are usually localized in the nucleolus, a dense zone in the nucleus. They are from 60 to 300nt in length and constitute a conserved class of small non-coding RNAs anciently spread by retrotransposition [35]. SnoRNAs are expressed in all eukaryotes, incorporated into small nucleolar ribonucleoprotein complexes (snoRNPs) with specific conserved protein partners to usually serve as guides for the chemical modifications of other non-protein-coding RNAs: either 2′-O-methylation of target RNAs (box C/D snoRNAs), or pseudouridylation (box H/ACA snoRNAs). However, recent studies revealed that snoRNAs display common features with miRNAs for their genomic location, processing pathways and integration in RISC complexes [36]. Although most snoRNAs were originally thought able to modify ribosomal RNAs for translation, a subgroup of snoRNAs has been shown to target small nuclear RNAs, tRNAs and mRNAs or even to be involved in rRNA processing.

Until very recently, snoRNA dysfunction had not been studied in cancer. However, works performing genomic analysis of snoRNAs in tumors highlighted their aberrant expression levels in cancer, including HCC [37]. Su and coworkers were the first to report in tumor tissues a frequent overexpression of fibrillarin, a protein component of C/D box snoRNP [38], in correlation with elevated amount of snoRNA clusters. Last year, the snoRNA snoU2_19, which is upregulated in HCC, has been found to play an oncogenic role through Wnt/β-catenin pathway activation [39]. Another snoRNA regulating the Wnt/β-catenin pathway and promoting liver tumorigenesis is SNORD76, whose expression is increased in HCC tissues and associated with poorer patient survival [40]. Altogether, these observations support potent roles of snoRNA pathways in cancer. It remains to unravel how snoRNAs are deregulated and precise their roles during tumorigenesis to open new opportunities for therapeutic intervention.

PiwiRNAs

piRNAs are preferentially detected in germ line and are usually 25—31nt in length [41]. They are characterized by their outstanding diversity of millions of sequences, poorly conserved but with a genomic localization commonly shared among species. The best-characterized class of piRNAs is repeat-associated piRNAs, guardians of transposon invasion. Another class of piRNAs called pachytene piRNAs, originating from the 3′UTR regions of mRNAs or from intergenic

lncRNAs, exhibits unknown targets and functions [42]. The mechanisms underlying piRNA biogenesis and functions are still elusive, due to the lack of easy-to-use *in vitro* models, and because little is common with the miRNA system. In contrast with miRNAs, repeat-associated piRNAs are produced from long single-stranded piRNA clusters independently to RNAse processing [43]. One mechanism of biogenesis is named ping-pong cycle creating secondary piRNAs, which target the initial piRNA clusters, amplifying the pattern of piRNAs. They bear 2′-O-methyl-modified 3′ termini recognized by the PIWI subfamily members of the Argonaute family, and prefer uracil in 5′-termini of their targets. By this repeated endonucleolytic cleavage, piRNAs guard the germline genome against detrimental DNA damage induced by multiplication and insertion of mobile transposons. Their major role aims at preserving spermatogenesis, a period of global epigenetic remodeling [44]. PiRNA-mediated transposon silencing could also be induced by epigenetic regulation during germline development by DNA and histone $H_3K_9me_3$ methylation [45]. PiRNAs are also required to silence the paternally imprinted gene *RASGFR1* during *de novo* methylation [46]. As a methylation inducer, the impact of piRNAs during cancer development could be a consistent question. These later years, some works have profiled piRNA expression and explored their biological functions in cancer, including liver cancer [47,48]. In particular, piR-Hep1 was found to be upregulated in half of HCC tumors and piR-Hep1 silencing inhibited cell viability, motility, and invasiveness *via* a reduction of AKT phosphorylation. The PIWI pathway also seems to be involved in the maintenance of cancer stemness and particularly in the resistance to chemotherapies [49]. These data gave new insights into liver tumorigenesis and support that piRNAs might be new disease biomarkers and could result in innovative treatment strategies.

Lon non-coding RNAs

LncRNAs are the class of ncRNAs, which currently knows the biggest attention from the scientific community. LncRNAs are transcribed by the RNA polymerase II from intergenic regions (lincRNAs), introns or enhancers in sense, antisense or bidirectional manner [50]. They are frequently polyadenylated. Their sequences are poorly conserved among species, challenging the comprehension of their underlying mechanisms. As for other ncRNAs, the number of lncRNAs is directly proportional to organism complexity. They exhibit a great diversity of sequences and structures and postulated to account for the majority of the non-coding transcriptome (50,000 lncRNAs are currently defined). LncRNAs display a tissue-specific pattern of expression and are finely regulated in time and space across the stages of development. In contrast to other ncRNAs, lncRNAs are predominantly nuclear and interact with ribonucleoproteins to control:

- transcription, either positively (ribosome guide, scaffold for transcriptional activators, chromatin remodelers, signal for transcription) or negatively (decoy, recruitment of transcriptional repressors);
- mRNA stability and translation (miRNA sponge);

- chromatin architecture (chromosome loops and inter-chromosomal interactions) [51].

Panels of lncRNAs have been shown to play essential roles during embryogenesis [52] and tumorigenesis [53], due to their regulatory roles in proliferation, differentiation, stress response and survival. Numbers of LncRNAs have been recently associated with HCC, and particularly with epithelial-to-mesenchymal transition (EMT), stem cell features and tumor invasion: lncRNA DANCR [54], hPVT1 [55], lncTCF7 [56] or ATB [57]. Others have been associated with HCC development and progression such as MEG3 [58], H19 [59], MALAT-1 [60] or TUG1 [61]. The first lncRNA identified as overexpressed in HCC is HULC (highly upregulated in liver cancer) [62], and thus the most studied. It regulates HCC proliferation, angiogenesis, lipid metabolism, autophagy and sensitivity to chemotherapies [63]. HULC expression predicts better outcomes [64] and may functions as a non-invasive potent biomarker [65]. Another interesting lncRNA is CASC9, upregulated in half of HCCs and associated with lower recurrence after surgery [66]. This study also highlights CASC9 as a putative non-invasive prognostic biomarker in HCC since higher level of circulating CASC9 is correlated with tumor size and HCC recurrence. Regarding to the large amount of lncRNAs implicated in HCC, these RNAs represent rational candidates for innovative therapy using RNAi approach, small inhibitory molecules or modulators of their secondary structures. The last three months, a study obtained encouraging results with nanoparticles delivering an inhibitor of the LncRNA TUG1, which exhibit antitumour activity on pancreatic and brain PDX (*patient-derived xenograft*) models [40]. In addition, MALAT-1 appears as a potent druggable lncRNA using LNA-Gapmer in multiple myeloma and probably other tumors [67], opening potential new avenues in molecular medicine based on lncRNAs.

Circular RNAs

As previously mentioned, the landscape of circRNAs has rapidly grown with improvement of next-generation sequencing, to reach more than 100,000 circRNAs identified in humans [68]. In most cases, circRNAs are generated by alternative splicing of pre-mRNAs called backsplicing but expressed independently of their linear isoforms [69]. Thus, circRNA biogenesis competes with linear splicing because of overlapping dependence on the spliceosome. Accordingly to their recent discovery, the understanding of how circRNAs participate in biological processes is still preliminary. However, circRNAs have been extensively described as microRNA sponges [70] but also as transcriptional and translational modulators [71]. Hundreds of circRNAs have been described deregulated in human cancers, including in liver cancer [72], and thus may serve as potential biomarkers [73]. They could act either as oncogenes or tumor suppressors through regulatory actions on cell proliferation, invasion or EMT [74]. Circ_100338 [75] and circ_0078602 [76] are associated with poor prognosis in HCC patients. CircRNA-based research is still in its infancy. The main challenge in future to make circRNAs as powerful candidates for cancer therapy will be circRNA targeting without detrimental interfering with linear RNA expression.

Exosomal ncRNAs as therapeutic and diagnostic candidates

Exosomes are double membrane cell-derived microvesicles from 30 to 100 nm in diameter, containing nucleic acids (> 3,400 mRNAs and 2,800 miRNAs according to Exocarta) and proteins (> 9700) [77]. Most cells, and particularly immune cells, are physiologically secreting exosomes originated from multivesicular bodies (MVB), whose fusion with the plasma membrane is orchestrated by Rab, SNAP (*Soluble N-ethylmaleimide-sensitive-factor attachment protein*) and SNARE (*SNAP Receptor*) proteins [78]. During tumorigenesis, tumor cells aberrantly secrete exosomes to communicate with stromal cells, such as the lncRNA TUC339 secreted from HCC cells towards the surrounding macrophages to promote tumor growth and spreading [79]. Interestingly, a very recent work reciprocally showed that adipose tissue secrete exosomal circRNA circ-DB (hsa_circ_0025129) to favor HCC growth, providing new insights into the understanding of the association between adipose tissue and HCC [80]. Exosomes are also useful for tumor cells to modify secondary recipient sites and to subsequently favor metastasis [81]. The detection of exosomal ncRNAs in body fluids is thus a valuable non-invasive diagnosis tool for cancer, including HCC. This has been extensively described in literature for miRNAs [26], such as miR-221 [82] or miR-224 [83], but also miR-21 and other ncRNAs like LncRNA-ATB [84], and circSMARCA5 [85].

Additionally, exosomes offer an attractive modality for personalized cancer treatment [86]. They have been used as a targeted delivery system for chemotherapeutic agents, leading to cancer cell killing and promoting a domino effect through the release of secondary cytotoxic vesicles [87]. Importantly, new encouraging works have been obtained by injection of stellate cell-derived exosomes in mice developing liver cancer. Exosomes incorporating mimics of miRNAs have successfully impaired tumor cell proliferation and favored apoptosis *in vivo* [88,89]. To avoid limitations associated with patient-derived exosomes (expensive and complex production, time consuming, poorly reproducible), a promising alternative is the synthesis of bioengineered exosome mimetics, more suitable for clinical use [90].

Conclusion

In conclusion, this review describes how ncRNA could represent in future promising tools for the treatment of liver cancer. The current advances in the field of nanotechnologies might facilitate delivery of ncRNA-based therapeutics in favor of clinical studies. Further studies are thus critically needed to precisely unravel the impact of ncRNA deregulations in cancer and how they could be counteracted to finalize clinical trials in the coming years.

Funding

Disclosure of interest

The authors declare that they have no competing interest.

References

[1] Lederberg J. The transformation of genetics by DNA: an anniversary celebration of Avery, MacLeod and McCarty (1944). Genetics 1994;136:423—6.

[2] Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, et al. Global identification of human transcribed sequences with genome tiling arrays. Science 2004;306:2242—6.

[3] Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860—921.

[4] Palazzo AF, Lee ES. Non-coding RNA: what is functional and what is junk? Front Genet 2015;6:2.

[5] Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007;316:1484—8.

[6] Ozata DM, Gainetdinov I, Zoch A, O'Carroll D, Zamore PD. PIWI-interacting RNAs: small RNAs with big functions. Nat Rev Genet 2019;20:89—108.

[7] Dupuis-Sandoval F, Poirier M, Scott MS. The emerging landscape of small nucleolar RNAs in cell biology. Wiley Interdisc Rev RNA 2015;6:381—97.

[8] Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol 2014;15:108—21.

[9] He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522—31.

[10] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009;10:155—9.

[11] Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005;30:106—14.

[12] Hock J, Meister G. The Argonaute protein family. Genome Biol 2008;9:210.

[13] Chen LL. Linking Long Noncoding RNA Localization Function. Trends Biochem Sci 2016;41:761—72.

[14] Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011;43:904—14.

[15] Veneziano D, Nigita G, Ferro A. Computational Approaches for the Analysis of ncRNA through Deep Sequencing Techniques. Front Bioeng Biotechnol 2015;3:77.

[16] Wang J, Zhang P, Lu Y, Li Y, Zheng Y, Kan Y, et al. piRBase: a comprehensive database of piRNA sequences. Nucleic Acids Res 2019;47. D175—80.

[17] Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human lncRNA transcript sequences and structures. Nucleic Acids Res 2013;41:D246—51.

[18] Alles J, Fehlmann T, Fischer U, Backes C, Galata V, Minet M, et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res 2019;47:3353—64.

[19] Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 2012;7 [e30733].

[20] Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002;297:2056—60.

[21] Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002;21:4663—70.

[22] Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834—8.

[23] Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955—63.

[24] Gougelet A. MicroRNAs linking cancer and inflammation: Focus on liver cancer. Springer; 2014.

[25] Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008;48:1810—20.

[26] Gougelet A, Colnot S. Hepatocellular carcinoma diagnosis: Circulating microRNAs emerge as robust biomarkers. Clin Res Hepatol Gastroenterol 2016;40:367—9.

[27] Teufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, Llovet JM, et al. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology 2019;156:1731—41.

[28] Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, et al. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut 2018;67:953—62.

[29] Huang KT, Kuo IY, Tsai MC, Wu CH, Hsu LW, Chen LY, et al. Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2017;9:274—83.

[30] von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, et al. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 2017;17:60.

[31] Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med 2013.

[32] Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, et al. Antitumour activity of an inhibitor of miR-34a in liver cancer with beta-catenin-mutations. Gut 2016;65:1024—34.

[33] Roberts J, Palma E, Sazani P, Orum H, Cho M, Kole R. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 2006;14:471—5.

[34] Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al., Phase I. study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 2017;35:180—8.

[35] Terns MP, Terns RM. Small nucleolar RNAs: versatile transacting molecules of ancient evolutionary origin. Gene Expr 2002;10:17—39.

[36] Scott MS, Ono M. From snoRNA to miRNA: Dual function regulatory non-coding RNAs. Biochimie 2011;93:1987—92.

[37] Yang H, Lin P, Wu HY, Li HY, He Y, Dang YW, et al. Genomic analysis of small nucleolar RNAs identifies distinct molecular and prognostic signature in hepatocellular carcinoma. Oncol Rep 2018;40:3346—58.

[38] Su H, Xu T, Ganapathy S, Shadfan M, Long M, Huang TH, et al. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene 2014;33:1348—58.

[39] Wang H, Ma P, Liu P, Chen B, Liu Z. Small nucleolar RNA U2_19 promotes hepatocellular carcinoma progression by regulating Wnt/beta-catenin signaling. Biochem Biophys Res Commun 2018;500:351—6.

[40] Wu L, Chang L, Wang H, Ma W, Peng Q, Yuan Y. Clinical significance of C/D box small nucleolar RNA U76 as an oncogene and a prognostic biomarker in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2018;42:82—91.

[41] Brennecke J, Aravin AA, Stark A, Dus M, Kellis M, Sachidanandam R, et al. Discrete small RNA-generating loci as

master regulators of transposon activity in Drosophila. Cell 2007;128:1089—103.

[42] Robine N, Lau NC, Balla S, Jin Z, Okamura K, Kuramochi-Miyagawa S, et al. A broadly conserved pathway generates 3'UTR-directed primary piRNAs. Curr Biol 2009;19:2066—76.

[43] Ishizu H, Siomi H, Siomi MC. Biology of PIWI-interacting RNAs: new insights into biogenesis and function inside and outside of germlines. Genes Dev 2012;26:2361—73.

[44] Carmell MA, Girard A, van de Kant HJ, Bourc'his D, Bestor TH, de Rooij DG, et al. MIWI2 is essential for spermatogenesis and repression of transposons in the mouse male germline. Dev Cell 2007;12:503—14.

[45] Kuramochi-Miyagawa S, Watanabe T, Gotoh K, Totoki Y, Toyoda A, Ikawa M, et al. DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine fetal testes. Genes Dev 2008;22:908—17.

[46] Watanabe T, Tomizawa S, Mitsuya K, Totoki Y, Yamamoto Y, Kuramochi-Miyagawa S, et al. Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse Ras-grf1 locus. Science 2011;332:848—52.

[47] Law PT, Qin H, Ching AK, Lai KP, Co NN, He M, et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol 2013;58:1165—73.

[48] Rizzo F, Rinaldi A, Marchese G, Coviello E, Sellitto A, Cordella A, et al. Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget 2016;7:54650—61.

[49] Weng W, Li H, Goel A. Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications. Biochim Biophys Acta Rev Cancer 2019;1871:160—9.

[50] Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012;22:1775—89.

[51] Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol 2017;18:206.

[52] Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell 2011;147:1537—50.

[53] Huarte M. The emerging role of lncRNAs in cancer. Nat Med 2015;21:1253—61.

[54] Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LL, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology 2016;63:499—511.

[55] Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 2014;60:1278—90.

[56] Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 2015;16:413—25.

[57] Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25:666—81.

[58] Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011;30:4750—6.

[59] Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007;2:e845.

[60] Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012;29:1810—6.

[61] Huang MD, Chen WM, Qi FZ, Sun M, Xu TP, Ma P, et al. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Mol Cancer 2015;14:165.

[62] Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132:330—42.

[63] Xiong H, Ni Z, He J, Jiang S, Li X, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017;36:3528—40.

[64] Yang Z, Lu Y, Xu Q, Tang B, Park CK, Chen X. HULC and H19 Played Different Roles in Overall and Disease-Free Survival from Hepatocellular Carcinoma after Curative Hepatectomy: A Preliminary Analysis from Gene Expression Omnibus. Dis Markers 2015;2015:1910—29.

[65] Li J, Wang X, Tang J, Jiang R, Zhang W, Ji J, et al. HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma. Cell Physiol Biochem 2015;37:687—96.

[66] Gramantieri L, Baglioni M, Fornari F, Laginestra MA, Ferracin M, Indio V, et al. LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget 2018;9:35085—99.

[67] Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia 2018;32:1948—57.

[68] Ji P, Wu W, Chen S, Zheng Y, Zhou L, Zhang J, et al. Expanded Expression Landscape and Prioritization of Circular RNAs in Mammals. Cell Rep 2019;26:3444—60 [e5].

[69] Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013;495:333—8.

[70] Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al., Natural RNA. circles function as efficient microRNA sponges. Nature 2013;495:384—8.

[71] Huang S, Yang B, Chen BJ, Bliim N, Ueberham U, Arendt T, et al. The emerging role of circular RNAs in transcriptome regulation. Genomics 2017;109:401—7.

[72] Fu L, Jiang Z, Li T, Hu Y, Guo J. Circular RNAs in hepatocellular carcinoma: Functions and implications. Cancer Med 2018.

[73] Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The Landscape of Circular RNA in Cancer. Cell 2019;176:869-81 [e13].

[74] Wang M, Yu F, Li P, Circular RNAs:. Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. Cancers (Basel) 2018;10.

[75] Huang XY, Huang ZL, Zhang PB, Huang XY, Huang J, Wang HC, et al. CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma. Front Oncol 2019;9:392.

[76] Kou P, Zhang C, Lin J, Wang H. Circular R.N.A. hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma. Oncol Lett 2019;17:2091—8.

[77] Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et al. ExoCarta: A Web-Based Compendium of Exosomal Cargo. J Mol Biol 2016;428:688—92.

[78] Thery C, Zitvogel L, Amigorena S, Exosomes:. composition, biogenesis and function. Nat Rev Immunol 2002;2:569—79.

[79] Li X, Lei Y, Wu M, Li N. Regulation of Macrophage Activation and Polarization by HCC-Derived Exosomal lncRNA TUC339. Int J Mol Sci 2018;19.

[80] Zhang H, Deng T, Ge S, Liu Y, Bai M, Zhu K, et al. Exosome circRNA secreted from adipocytes promotes the growth of

hepatocellular carcinoma by targeting deubiquitination-related USP7. Oncogene 2019;38:2844—59.

[81] Kalluri R. The biology and function of exosomes in cancer. J Clin Invest 2016;126:1208—15.

[82] Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70—3.

[83] Lin L, Lu B, Yu J, Liu W, Zhou A. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage. Clin Res Hepatol Gastroenterol 2016;40:397—404.

[84] Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, Park JG, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer 2019;144:1444—52.

[85] Li Z, Zhou Y, Yang G, He S, Qiu X, Zhang L, et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta 2019;492:37—44.

[86] Gougelet A. Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. World J Hepatol 2018;10:785—9.

[87] Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun 2012;3:1282.

[88] Li L, Piontek K, Ishida M, Fausther M, Dranoff JA, Fu R, et al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology 2017;65:501—14.

[89] Wang F, Li L, Piontek K, Sakaguchi M, Selaru FM. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 2018;67:940—54.

[90] Wu JY, Ji AL, Wang ZX, Qiang GH, Qu Z, Wu JH, et al. Exosome-Mimetic Nanovesicles from Hepatocytes promote hepatocyte proliferation in vitro and liver regeneration in vivo. Sci Rep 2018;8:2471.